Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by NewEdge Advisors LLC

NewEdge Advisors LLC cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 82.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,316 shares of the biopharmaceutical company’s stock after selling 10,701 shares during the quarter. NewEdge Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $766,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. Geneos Wealth Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 175 shares during the period. Flow Traders U.S. LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $241,000. Daiwa Securities Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after buying an additional 35 shares during the last quarter. Finally, Nebula Research & Development LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $293,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALNY. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a report on Friday, July 31st. Sanford C. Bernstein raised Alnylam Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. reduced their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Royal Bank Of Canada lowered their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Finally, Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.62.

Alnylam Pharmaceuticals Stock Up 6.1%

Alnylam Pharmaceuticals stock opened at $242.61 on Thursday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The firm has a 50 day moving average price of $269.15 and a 200 day moving average price of $298.51. The company has a market capitalization of $32.46 billion, a PE ratio of 45.09 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the company earned ($0.51) earnings per share. The firm’s quarterly revenue was up 66.9% compared to the same quarter last year. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Insider Activity

In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.